Mitchell J, Frishman W, Heiman M
Department of Medicine, Albert Einstein College of Medicine, Bronx, New York.
J Clin Pharmacol. 1993 Jan;33(1):46-52. doi: 10.1002/j.1552-4604.1993.tb03902.x.
Nisoldipine is a new calcium-channel blocker of the dihydropyridine subclass, with a chemical structure similar to nifedipine. It has been used in clinical trials to assess its efficacy and safety in patients with hypertension, angina pectoris, and congestive heart failure. Similar to other dihydropyridines, nisoldipine is a potent peripheral and coronary dilator. The most optimal dosage regimen has not been established in clinical trials. The drug appears to have a favorable side-effect profile.
尼索地平是一种新型的二氢吡啶类钙通道阻滞剂,其化学结构与硝苯地平相似。它已被用于临床试验,以评估其在高血压、心绞痛和充血性心力衰竭患者中的疗效和安全性。与其他二氢吡啶类药物相似,尼索地平是一种强效的外周血管和冠状动脉扩张剂。临床试验中尚未确定最优化的给药方案。该药物似乎具有良好的副作用谱。